Abingdon Health PLC - rapid tests manufacturer - Signs a non-exclusive sales & distribution agreement in the UK and Europe for the AbC-19 rapid neutralising antibody test with BioSure UK. Under the terms of the agreement, both companies intend to establish a strategic distribution relationship to enable them to identify and maximise opportunities for the sale of the AbC-19 test in the UK and European territories.
"Rapid Antibody tests such as AbC-19 that target the full trimeric spike can help policymakers and healthcare networks further understand immunity to Covid-19 and the effectiveness of vaccine programmes," says Abingdon Health Chief Execuitve Chris Yates.
Current stock price: 103.44 pence, up 7.2% on Wednesday
Year-to-date change: up 9.4%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Abingdon Healt. (ABDX)